There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | GYeon Oh |
| Institution: | University of Kentucky |
| Department: | Sanders-Brown Center on Aging |
| Country: | |
| Proposed Analysis: | The gabapentin prescriptions which was approved by the US Food and Drug Administration to treat partial seizures and postherpetic neuralgia has been increased in the elderly. However, up to 95% of gabapentin prescriptions has been prescribed for off-label indications, such as alternative to opioid therapy and treatment for behavior and psychiatric symptoms. Antiepileptic drugs are known to affect cognition by suppressing neuronal excitability or enhancing inhibitory neurotransmission; however, the association between gabapentin and cognition has been unknown, with conflicting results. Considering one of the possible mechanisms of gabapentin is blocking calcium channel in the brain, we hypothesize that use of gabapentin could have protective effect on the cognitive changes in the older adults. Therefore, we aim to examine the change of neuropathologic outcomes, brain volume, and biomarkers of older adults with MCI who have reported to use gabapentin using ADNI data. |
| Additional Investigators | |
| Investigator's Name: | Daniela Moga |
| Proposed Analysis: | The gabapentin prescription, which was approved by the US Food and Drug Administration to treat partial seizures and postherpetic neuralgia, has been increased in the elderly. However, up to 95% of gabapentin prescriptions have been prescribed for off-label indications, such as an alternative to opioid therapy and treatment for psychiatric symptoms. Antiepileptic drugs are known to affect cognition by suppressing neuronal excitability or enhancing inhibitory neurotransmission; however, the association between gabapentin and cognition has been unknown, with conflicting results. Considering one of the possible mechanisms of gabapentin is blocking calcium channel in the brain, we hypothesize that gabapentin could have a protective effect on the cognitive changes in older adults. Therefore, we aim to examine the change of neuropathologic outcomes, brain volume, and biomarkers of older adults with MCI who have reported to use gabapentin using ADNI data. |
| Investigator's Name: | Erin Abner |
| Proposed Analysis: | The gabapentin prescription, which was approved by the US Food and Drug Administration to treat partial seizures and postherpetic neuralgia, has been increased in the elderly. However, up to 95% of gabapentin prescriptions have been prescribed for off-label indications, such as an alternative to opioid therapy and treatment for psychiatric symptoms. Antiepileptic drugs are known to affect cognition by suppressing neuronal excitability or enhancing inhibitory neurotransmission; however, the association between gabapentin and cognition has been unknown, with conflicting results. Considering one of the possible mechanisms of gabapentin is blocking calcium channel in the brain, we hypothesize that gabapentin could have a protective effect on the cognitive changes in older adults. Therefore, we aim to examine the change of neuropathologic outcomes, brain volume, and biomarkers of older adults with MCI who have reported to use gabapentin using ADNI data. |
